Company engaged a leading clinical center in Israel and intends to conduct its first- in- human trial in the United States as well Tel Aviv, Israel / Vancouver, Canada, Dec. 28, 2022 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the “company”), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve…

Source

Previous articlePT379 – Intergenerational Trauma, Late-Stage Capitalism, and the Urban Indigenous Collective
Next articleClearmind Medicine Announces Shareholders Meeting Results